The EvoPAR-Prostate02 clinical trial is a Phase 3 research study evaluating saruparib (AZD5305), an investigational PARP1 inhibitor, in men with high-risk or very high-risk BRCA1- or BRCA2-mutated prostate cancer. The study is investigating whether adding saruparib to standard treatment—including radiation therapy and androgen deprivation therapy (ADT)—can help prevent the cancer from spreading and improve long-term outcomes.
This educational discussion explains why BRCA genetic testing is becoming an important part of prostate cancer care, how PARP inhibitors work, and what patients should know before considering participation in the EvoPAR-Prostate02 clinical trial. It also addresses common questions about eligibility, side effects, placebo use, and what participation in a clinical trial involves.
Featured Experts
- Dr. Keith Crawford, Director of Clinical Trials and Patient Education, PHEN
- Dr. Rana McKay, Genitourinary Medical Oncologist and Clinical Trial Investigator, University of California, San Diego
Topics Covered
- Understanding high-risk and very high-risk prostate cancer
- Why BRCA1 and BRCA2 genetic testing matters
- Germline versus tumor (somatic) genetic testing
- How PARP inhibitors, including saruparib, work
- Overview of the EvoPAR-Prostate02 Phase 3 clinical trial
- Radiation therapy and androgen deprivation therapy (ADT)
- Understanding placebo-controlled clinical trials
- Potential side effects and safety monitoring
- Costs, eligibility, and participation expectations
- Questions patients should ask their healthcare team before joining a clinical trial
Whether you are newly diagnosed with high-risk prostate cancer or exploring treatment options after learning you carry a BRCA mutation, this discussion provides practical, easy-to-understand information to help you have informed conversations with your healthcare team.
Read full blog: Understanding the EvoPAR-Prostate02 Clinical Trial | BRCA Testing and PARP inhibitors for High-Risk Prostate Cancer
To learn more about prostate cancer clinical trials or explore studies you may qualify for, visit PHENTrials.com.
